FELBINAC

First approved in 2018

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H12O2
Molecular Weight	212.2439
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2

InChI

InChIKey=QRZAKQDHEVVFRX-UHFFFAOYSA-N

InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)

HIDE SMILES / InChI

Molecular Formula	C14H12O2
Molecular Weight	212.2439
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.medicines.org.uk/emc/PIL.29400.latest.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7002162

Felbinac, an active metabolite of fenbufen, is two times more potent than the parent drug. Felbinac is used topically to alleviate pain in the joints and muscles caused by injury or inflammation (Trixam 3% gel or foam). The drug is believed to exert its action by inhibiting COX-2 protein.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 2 48 Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7002162	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain in the joints and muscles 2 Sources: https://www.hpra.ie/img/uploaded/swedocuments/2135395.PPA1151_081_001.0b9c827c-5e67-4484-8e8a-21525cc74ebd.000001Product%20Leaflet%20Approved.130823.pdf	Primary		Approved 8429	TRAXAM Approved Use Traxam Gel is used for the relief of pain in the joints and muscles caused by injury or inflammation. It is used for the treatment of the following conditions: sprains, strains, bruising, rheumatic or arthritic conditions, frozen shoulder, tennis elbow or other joint injuries.

PubMed

Title	Date	PubMed
Biphenylacetate, but not theophylline, lethally interacts with ciprofloxacin in mice.	1993 Nov	8115312
Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice.	1993 Sep	7902066
Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid.	1997 Nov	9347323
Topical non-steroidal drugs are systemically absorbed and may cause renal disease.	1999 Jan	10052505
Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide.	2001 Nov 21	12240066
Synthetic applications of o- and p-halobenzyl sulfones as zwitterionic synthons: preparation of ortho-substituted cinnamates and biarylacetic acids.	2002 Jul 26	12126409
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].	2002 Jun	12199111
Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer.	2002 Jun 4	12052698
Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation.	2004 Jul 2	15117964
Changes in brain interleukin-1beta following the coadministration of norfloxacin with biphenylacetic acid in rats.	2006 Aug 14	16824509
Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems.	2006 Jan	16365667
Synthesis and pharmacological evaluation of some dual-acting amino-alcohol ester derivatives of flurbiprofen and 2-[1,1'-biphenyl-4-yl]acetic acid: a potential approach to reduce local gastrointestinal toxicity.	2006 Nov	17193237
Percutaneous penetration of felbinac after application of transdermal patches: relationship with pharmacological effects in rats.	2008 Jan	18088507
Analgesic effect of percutaneously absorbed non-steroidal anti-inflammatory drugs: an experimental study in a rat acute inflammation model.	2008 Jan 31	18234123
Stepwise two-color laser photolysis studies of alpha-cleavage in highly excited triplet states of alpha-acyl-4-phenylphenols.	2008 Jun	18528556
Mechanisms of drug release in citrate buffered HPMC matrices.	2009 Mar 31	19100822
Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison.	2009 Sep 21	19772573
Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch.	2010 Nov 10	21197326
2-(Biphenyl-4-yl)acetic acid (felbinac).	2010 Sep 25	21587585

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is about one inch or 2.5cm (which is about one gram) of gel rubbed into the affected area two to four times a day.

Route of Administration: Topical

In Vitro Use Guide

A 0.12 mM concentration of felbinac (BPAA) produces almost complete inhibition of arachidonate-induced aggregation of blood platelets.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:35:45 UTC 2023` Edited by `admin` on `Fri Dec 15 17:35:45 UTC 2023`
Record UNII	94WNJ5U8L7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FELBINAC

Official Name

English

4-Biphenylacetic acid

Systematic Name

English

(1,1'-BIPHENYL)-4-ACETIC ACID

Systematic Name

English

NSC-16284

Code

English

DOLINAC

Brand Name

English

LY-61017

Common Name

English

FELBINAC [JAN]

Common Name

English

TRAXAM

Brand Name

English

felbinac [INN]

Common Name

English

CL-83544

Code

English

FELBINAC [USAN]

Common Name

English

CL 83,544

Code

English

LJC-10141

Code

English

FELBINAC [MI]

Common Name

English

Felbinac [WHO-DD]

Common Name

English

LJC 10,141

Code

English

NAPAGELN

Brand Name

English

L-141

Common Name

English

FELBINAC [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-ATC

M02AA08